HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Lewis, S. Articles by Lieberman, J. PubMed PubMed Citation Articles by Lewis, S. Articles by Lieberman, J.

CATIE and CUtLASS: can we handle the truth?

Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK

Jeffrey Lieberman, MD

Department of Psychiatry, College of Physicians and Surgeons, Columbia University and New York State Psychiatric Institute, and Lieber Center for Schizophrenia Research, and New York Presbyterian Hospital and Columbia University Medical Center, New York, USA

Correspondence: Professor Shôn Lewis, University of Manchester University Place (3rd floor east), Stopford Building, Oxford Road, Manchester M13 9PL, UK. Email: shon.lewis{at}manchester.ac.uk

Declaration of interest

S.L. is the Chief Investigator of the CUtLASS study and J.L. is the Chief Investigator of the CATIE study. S.L. has received honoraria from several pharmaceutical companies. J.L. has received research funding from several pharmaceutical companies.

Shôn Lewis (pictured) is Head of the Psychiatry Research Group at the University of Manchester. His research interests focus on risk factors and interventions in early psychosis. Jeffrey Lieberman is Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. His research has centred on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders.

Two large, non-commercial clinical trials comparing first- and second-generation antipsychotic drugs for people with chronic schizophrenia in the US and UK have shown unexpected results. In general, the newer drugs were no more effective or better tolerated than the older drugs. Clozapine outperformed other second-generation drugs. The implications are considered.

View larger version (131K): [in this window] [in a new window] [as a PowerPoint slide]

Related articles in BJP:

From The Editor's Desk

Peter Tyrer
BJP 2008 192: 242. [Full Text]  

Highlights of this issue

Sukhwinder S. Shergill
BJP 2008 192: 10. [Full Text]  

This article has been cited by other articles:

				M. Shuchman MD and P. C. Hebert MD MHSc Bringing a research base to psychiatry Can. Med. Assoc. J., May 6, 2008; 178(10): 1257 - 1258. [Full Text] [PDF]

				M. Shuchman MD and P. C. Hebert MD MHSc Etablir une base de recherche en psychiatrie Can. Med. Assoc. J., May 6, 2008; 178(10): 1259 - 1260. [Full Text] [PDF]

eLetters: